Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pharming Group ( (PHGUF) ) has provided an update.
Pharming Group announced the appointment of Fabrice Chouraqui as the new Executive Director and Chief Executive Officer, succeeding Sijmen de Vries. This leadership change, approved at the Extraordinary General Meeting, aims to strengthen Pharming’s position in the rare disease market, with de Vries remaining as a strategic advisor until the end of 2025.
More about Pharming Group
Pharming Group N.V. is a global biopharmaceutical company focused on transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is engaged in commercializing and developing a portfolio of protein replacement therapies and precision medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and operates in over 30 markets worldwide.
YTD Price Performance: -8.57%
Average Trading Volume: 1,828
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $616.7M
Find detailed analytics on PHGUF stock on TipRanks’ Stock Analysis page.